Title for MeetingAbstracts
Alphabetical listing of titles
-
Activity of Gemifloxacin (SB-265805) Compared with Other Quinolones against Quinolone-Resistant Pneumococci.
-
Activity of Gemifloxacin and Comparative Fluoroquinolones (FQs) against Isolates of Streptococcus pneumoniae (SPN) with Reduced Susceptibility to Ciprofloxacin.
-
Activity of Gemifloxacin and Other Fluoroquinolones against DNA Gyrase and Topoisomerase IV from Haemophilus influenzae.
-
Activity of Gemifloxacin, Ciprofloxacin and Levofloxacin against 8579 Respiratory Isolates Collected Worldwide in 2000.
-
Activity of GM-CSF and M-CSF upon replication of HIV and other DNA-RNA-viruses in primary macrophages.
-
Activity of HMR 3787, a New Fluoroketolide, and Its (Des)-Fluor-Derivative RU 64399 Compared to Those of Five Other Agents Against Group A Streptococci.
-
Activity of Iclaprim against Penicillin, Erythromycin, Trimethoprim/Sulfamethoxazole or Ciprofloxacin Resistant Streptococcus pneumoniae from Canada.
-
Activity of Iclaprim and Comparators against Atypical Bacterial Respiratory Pathogens.
-
Activity of Intravenous (IV) LY 333328 (LY) Alone or Combined with Gentamicin (Ge) In Vitro and in Experimental Endocarditis Caused by Enterococcus faecalis.
-
Activity of Ketolides HMR 3562 and HMR 3787 against Erythromycin-Sensitive (Ery-S) and -Resistant (Ery-Rc) Pneumococci in Murine Pneumonia Models.
-
Activity of Linezolid (LIN) Against Medically Important Gram-Positive Bacteria from 1997 to 1999.
-
Activity of Linezolid Combined with Quinolones and Novobiocin.
-
Activity of Linezolid on Antibiotic-Resistant and -Susceptible Strains of Streptococcus pneumoniae Collected from across Canada.
-
Activity of masked 2'-3'-dideoxynucleoside-monophosphate derivatives against human immunodeficiency virus in resting macrophages. Eleventh International Conference on Antiviral Research.
-
Activity of Melaleuca alternifolia against Non-Triazole Susceptible (nTS) Candida Species (CS) by the NCCLS M27-A2 Microbroth (MB), Sensitre YeastOne (SYO), and Time-Kill (TK) Methods.
-
Activity of MK-0826 against Clinical Strains of Cephalosporin Resistant Enterobacteriaceae, Including Strains Bearing Extended Spectrum b-lactamases (ESBL).
-
Activity of Moxifloxacin (MXF) against Bacteroides fragilis in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model in Single and Mixed Cultures.
-
Activity of Moxifloxacin (MXF) against Resistant and Susceptible Populations of Streptococcus pneumoniae (SP), Haemophilus Influenzae (HI), and Moraxella catarrhalis (MC) Isolated in the United States.
-
Activity of Moxifloxacin against Invasive and Multiresistant Pneumococci from England and Wales.
-
Activity of Moxifloxacin in the Treatment of Tuberculosis in a Murine Model.
-
Activity of N-Acetylcysteine Alone or in Association with Ribavirin in a Mouse Model of Influenza Viral Infection.
-
Activity of Nalidixic Acid and 6 Fluoroquinolones against 315 Isolates of Salmonella no Thypi.
-
Activity of New 1b-Methylcarbapenem J-114,870 with Unusual Antibacterial Spectrum Including Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
-
Activity of New Ciprofloxacin and Norfloxacin Derivatives against Several Fluoroquinolone Resistant Bacteria.
-
Activity of New Quinolones, Macrolide, and Ketolide Against 100 Strains of Legionella Species Using Broth Dilution and Intracellular Susceptibility Testing Methods.
-
Activity of Newer Fluoroquinolones (FQ) against Isolates of Streptococcus pneumoniae (SPN) with Increasing Resistance to Ciprofloxacin.
-
Activity of Nisin, Alone and in Combination, vs MRSA and VRE.
-
Activity of Novel Acyclic Pyrimidine Nucleoside Phosphonates against Different DNA Polymerase Mutants of Herpes Simplex Virus Type 1 (HSV-1).
-
Activity of Novel Peptide Deformylase (PDF) Inhibitors against Atypical Bacterial Respiratory Pathogens.
-
Activity of nucleoside and non-nucleoside reverse transcriptase inhibitors (NNRTI) against equine infectious anemia virus (EIAV).